AbbVie Profit Jumps 24% as Humira Sales Rise


AbbVie Inc reported a 24 percent jump in quarterly profit due to higher sales of its arthritis drug, Humira, and the inclusion of sales of Pharmacyclics' blood cancer drug, Imbruvica.

Continue Reading Below

AbbVie's net profit rose to $1.37 billion, or 83 cents per share, in the second quarter ended June 30 from $1.10 billion, or 68 cents per share, a year earlier.

Revenue rose 11 percent to $5.48 billion.

AbbVie completed the acquisition of Pharmacyclics on May 26, giving it about one month's revenue from Imbruvica. (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)